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The tools of molecular biology and biotechnology has appeared
more under the more general nomenclature of gene therapy, and
other subsidiary nomenclature including gene editing, gene
replacement, gene insertion, gene targeting and the likes. However,
molecular biology and biotechnology are indeed, bigger than these
nomenclatures; fortified with a broader scope. The clear under-
standing of the cellular and molecular mechanisms is at the heart
of this form of therapy involving modification of the blueprint of
life. It is about three decades ago from now that the idea of gene
therapy was carried to the clinic to be tried as an alternative
method of approaching diseases in a way that pharmacotherapy
couldn’t prove efficient, with about 3000 clinical trials in record.
This was not without associated side effects or adverse reactions
though. Highly sophisticated gene transfer tools vastly equipped
with improved therapeutic efficacy as well as taking safety into
consideration has been developed to address the basic challenges
that face this therapeutic method. Such sophisticated tools may
include viral and non-viral vectors, naked oligonucleotides as well
as plasmids. With the particular improvement, a series of clinical
trials have been conducted with recorded successes with overtly
no side effects, with cancer gene therapy accounting now for the
majority of clinical trials worldwide (http://www.wiley.com/legacy/wileychi/genmed/clinical/). A notable instance is Gen-
dicine, an adenovirus-p53 based gene therapeutic that gained
approval into the market for head and neck squamous cell carci-
noma treatment, depicting an early evidence of molecular Biology
relieving pharmacotherapy of burden [1]. It remarkably showed
desired results without overt side effects even after a record of
treatment of over 10,000 patients. The gene therapy area of medi-
cine has focused more on the correction of inherited diseases. Sim-
ilarly, trailing the fate of Gendicine in 2012, is Glybera
(tiparvovec) an alipogene, which also gained a commercial
approval for the treatment of familial lipoprotein lipase deficiency
(LPLD) [2]. These are obvious milestones in clinical medicine. Gene
therapy generally involves the introduction of new therapeutic
genes (Table 1) encoded by nucleic acids (DNA), alteration/modifi-
cation of existing genes or the introduction of RNA into cells, for
the prevention, treatment or cure of disorders and diseases, in
order to restore or add gene expression. Most commonly, a faulty
or missing gene is substituted with a copy of DNA encoding the
desired function. Orphan diseases with damaging monogenetic
defects, including primary immunodeficiencies (PID), were the
early focus of gene therapy, but this has greatly expanded to cut
across a number of diverse disorders and diseases which include
Parkinson’s disease, diabetes, heart failure, cancers and other neu-
rodegenerative or metabolic disorders. [3]. There are however, a lot
of hurdles that gene based therapeutics have to go through before
they get to final commercial use. Some major challenges such as
the recognition of the protein on the viral capsid by the host
immune system has been managed by the development of
Table 1
Gene types transferred in Gene therapy clinical trials. Data Sourced from: The Journal
of Gene Medicine (www.wiley.co.uk/genmed/clinical) on 2nd June 2017.
Gene type Gene Therapy Clinical Trials
Number Percentage (%)
Growth factor 176 7.1
Antigen 474 19.2
Antisense 17 0.7
Cell cycle 10 0.4





Oncogene regulator 12 0.5
Oncolytic virus 52 2.1
siRNA 11 0.4
Cell protection/Drug resistance 20 0.8
Receptor 259 10.5
Replication inhibitor 94 3.8
Ribozyme 6 0.2
Tumor suppressor 181 7.3
Suicide 173 7
Transcription factor 35 1.4
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inflammatory activities, thereby producing excellent safety profile
even for in vivo gene therapy [4]. There are many gene transfer
mechanisms available and could be in vivo or in vitro. For instance,
Glybera is a recombinant adeno-associated virus-derived vector
(AAV) for direct intramuscular injection. Very recent protocols
involved in gene therapy involves cell isolation from the benefi-
ciary (patient) followed by genetic modification in vitro, thereafter
re-introduction (reinfusion) into the beneficiary. One of the key
advantages of this protocol outside the body is that, adverse reac-
tions and side-effects are reduced to a feasible minimum. It also
gives room for the administration of the desired concentration,
since they will be no detoxification load on the liver and the renal
system. The pioneering inspiration for the initiation of the gene
therapy trial to correct adenosine deaminase (ADA) deficiency
using genetically modified T-lymphocytes came from the pioneer
work of Rosenberg et al., at NCI. The first application of genes-mod-
ified haematopoietic cells was carried out by inserting a gene from
bacteria into lymphocytes that are capable of infiltrating tumours
in order to track the associated behaviors of melanoma cells after
they are administered into the patients [5,6]. They are quite a num-
ber of successful clinical trials that buttresses the fact that virtually
a lot more can also be done via the modification of T-cells such as
the incorporation of chimeric antigen receptors (CAR) to enhance
tumour cell recognition aimed at facilitating a fleet of cancer killing
cells to the target [7]. One single great achievement in gene ther-
apy advances is the development of inducible suicide genes,
inserted into allograft of T-cells; capable of being activated upon
GvHD development. This permits patient-specific alloreactivity
modulation [8,9]. Similar approaches have also been applied to
skin diseases (e.g. epidermolysis bullosa), as well as liver diseases
(familial hypercholesterolemia) [10] in vivo and ex vivo [11]. Ther-
apeutic gene therapy holds better promises for us in treating dis-
eases (including hemoglobinopathies, cancer immunotherapies,
haemophilia B, ocular diseases, neurological diseases [12],
immunological, metabolic disorders, ocular, neurodegenerative,
hematological and other primary immune deficiencies) that have
eluded cure, than the more commonly available temporary or sub-
optimal methods of treatments. We do not yet rule-out completelythe occurrence of setbacks, as many limitations are also associated
with these breakthroughs; as in the case of later development of
leukemia in which some patients died, however, we have recorded
the ‘‘comeback of gene therapy” [13,14]. Rapid improvements are
recorded every year (Fig. 1). Vision of blind patients have been
restored, hematopoietic stem cells has been used to terminate
incurable blood cancers (though expensive as well as incurring
high risks), restoring immunity in patients. Thousands of clinical
and experimental trials are in the pipeline towards improving all
the factors surrounding the desired success in gene therapy
(Table 2). One of the simplest aims of gene therapy is to outper-
form conventional medications by searching for methods of treat-
ing diseases; reassigning functional non-deficient therapeutic
nucleic acids to a patient’s hosting cell (gene editing) with the tar-
get of correcting a defective gene. It therefore intends to redefine
diseases that were previously classified untreatable as curable
(which include primary immune deficiencies and ocular diseases).
Progress in optimized vector systems design for ex vivo as well as
in vivo gene transfer have become a true potential for treating var-
ious disease with vastly increased spectrum of medical application
beyond genetic disorders; for example blood cancers by means of
chimeric antigen receptor (CAR)-modified T-cells [15], that were
formally incurable due to setbacks associated with vectors. Clinical
gene and cell therapy approach are founded on either ex vivo gene
incorporation into autologous tissues/cells such as hematopoietic
stem cells (HSC) to treat basically hematological as well as other
disorders, not excluding immunotherapy via differentiated lin-
eages. For instance T lymphocytes; then an adoptive back-transfer
afterwards into the recipient (patient) or in vivo gene insertion into
post-mitotic target tissues/cells. So far, the adeno-associated virus
(AAV) vectors (for instance, Glybera, for treating lipoprotein lipase
deficiency) have been established to be of utmost clinical accom-
plishment for in vivo gene delivery in the midst of the range of viral
based vector systems [15]. Lentiviral (LVs; having a better preclin-
ical safety report use for non-dividing cells than c-retroviral) or
c-retroviral-derived retroviral vectors have the ability to integrate
their therapeutic genetic modification into the genome (proven in
hematopoietic cells) of the target cells [16,17]. The aim of this
study therefore is to enlighten on how the tools of molecular biol-
ogy and biotechnology such as adeno-associated virus (AAV) vec-
tors and Self-inactivating (SIN) Channels therefore relieves
Pharmacotherapy of a lot of burdens. This form of rescue for phar-
macotherapy has been there for decades, but it’s important to point
out and get the scientific community updated on the strides
recorded in most recent years as it will be useful to all concerned
specialists available solutions in the scene of medicine concerning
a particular disease.2. Current redirections in gene therapy
In addition to the advances made in molecular biology and
biotechnology as applied to molecular gene therapy aimed at alle-
viating the setbacks and challenges associated with the more con-
ventional pharmacotherapy, there are yet some recent novel
attempts at improving on the existing strategies. The last decade
has made a very drastic contribution to this field and a few of such
recent contributions are discussed and some of the systematic
headings that follow.2.1. Using AAV-derived vectors as substitutes for integrating vectors
As stated earlier, developments in optimized vector organiza-
tion designs for ex vivo as well as in vivo gene transfer is on the rise
(Table 3). Retroviral as well as lenti-viral vectors have been effec-
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Fig. 1. The number of Gene Therapy Clinical Trials approved worldwide before, and from 1989–2016, as updated in August 2016. Data Sourced from: The Journal of Gene
Medicine (www.wiley.co.uk/genmed/clinical) on 2nd June 2017.
Table 2
Phases of Gene Therapy Clinical Trials. Data Sourced from: The Journal of Gene
Medicine (www.wiley.co.uk/genmed/clinical) on 2nd June 2017.
Clinical Trial Phase Number (n) Percentage (%)
Phase I 1409 57.20%
Phase I/II 500 20.30%
Phase II 429 17.40%
Phase II/III 24 1%
Phase III 93 3.80%
Phase IV 3 0.10%
Single subject 5 0.20%
Total 2463 100%
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tissue AAV vectors are being considered as the better alternative
delivery tool. The remarkable advantage of the alternative method
is that AAV vectors are equipped with a protein capsid that is
non-enveloped as well as a DNA genome that could be a
single-stranded DNA in its native conformation form or as a
self-complementary DNA in its artificial conformation [18]. The
artificial conformation provides the ability to fold into a double-
stranded conformation. Upon release from the viral capsid [19],
the double-stranded conformation is made possible by the intra-
molecular base pairing of the aligning complementing bases
producing a significantly improved onset of transgene expression
at the expense of the lessening of the coding capacity from approx-
imately 5 to 2.5 kb (50%) [20,21]. This parent AAV vectors are gut-
less, non-pathogenic (deficient of all viral open reading frames,
therefore, they remain principally in an episomal structure) with
the inability to self-replicate, however, with the help of the
inverted terminal repeats (ITRs) they retain the ability to integrate
their genome in the human genome, specifically on a specific site
(AAV integration site 1, 19q13.3-qter, AAVS1) on chromosome 19
[20]. The AAV vector genomes episomal nature, not withstanding,
they can be integrated into the genome of the target cells with fre-
quency that could be as high as of 104–105. One great advantage
with this is that there is no preference for any specific genomic loci
[22,23]. This remarkable adaptability of these AAV vectors has
made them clinically applicable in diverse therapy includingcentral nervous system, liver, retina, cardiac muscle and skeletal
muscles as specific targets [19,24–28]. This characteristic property
of AAV pronounces it a non-integrating vector system, which
brings to light the fact that long term correction is only regimented
to post-mitotic tissue. For instance, Leber’s congenital amaurosis
(LCA) (an early onset retinal dystrophy), characterized by a mal-
function and deterioration of photoreceptors is caused by muta-
tions in retinal pigment epithelium-specific protein 65 kDa
(RPE65) gene [29–31]. This gene codes for a retinoid isomerase;
a key factor in retinol function in the visual cycle [28,31,32], by
using specific hRPE65 (resulting in a lower expression) or ubiqui-
tously promoters (higher expression), after the injection of AAV2
vectors to the subretina, the over-expression of a functional copy
of the gene RPE65 could improve vision [30]. As shown from the
low immunogenicity, safety, clinical benefit and good tolerability,
in three previous clinical trials, the immune system is an impor-
tant factor that must be considered in all kinds of experimental
and clinical research practices [28]. For instance, the reactivation
of memory T-cell responses which results in the loss of vector-
modified cells, providing the attenuation therapeutic efficacy, as
opposed to the muscle- and liver-directed gene therapy applica-
tions [18,33], subretinal injection of AAV vectors would mount
low humoral immune responses. In attempting to cure RPE65-
associated LCA, a lasting improvement in vision is achievable by
RPE65 overexpression with a continuous degeneration of the pho-
toreceptor (a setback that must be counterbalanced by other inter-
ventions), measurable by taking the dimensions of the outer
photoreceptor layer width [32]. Gene therapy has been duly pro-
ven to be safe with reported clinical scores. These include Canavan
disease, LCA and others yet in progress. Correspondingly, in order
to treat patients with advanced Parkinson’s disease, locally
injected AAV2 vectors unilaterally into subthalamic nucleus [24],
designed to express glutamic acid decarboxylase (GAD) into the
subthalamic nucleus produces improvements in safe and tolerable
clinical achievements with evidences in clinical trials [34]. In
Canavan disease, using AAV2 vectors, the aspartocylase gene
(ASPA) which codes for the enzyme that is required for the degra-
dation of N-acetyl-aspartate (NAA) is transported to the brain
leading to the stabilization of the atrophy of the brain, alongside
Table 3
Vectors used in Gene Therapy Clinical Trials. Data Sourced from: The Journal of Gene




Alphavirus (VEE) Replicon Vaccine 1 0
E. coli 2 0.1
Bifidobacterium longum 1 0
CRISPR-Cas9 7 0.3
Adenovirus + Sendai virus 1 0
Adenovirus + Vaccinia virus 8 0.3
Antisense oligonucleotide 6 0.2
Vaccinia virus 125 5.1
Venezuelan equine encephalitis virus replicon 3 0.1
Vesicular stomatitis virus 3 0.1
Vibrio cholerae 1 0
Flavivirus 8 0.3
Gene gun 5 0.2
Herpes simplex virus 90 3.7
Lactococcus lactis 6 0.2
Lentivirus 158 6.4
Lipofection 116 4.7
Adeno-associated virus 183 7.4
Adenovirus 509 20.7
Adenovirus + Modified vaccinia Ankara virus (MVA) 11 0.4
Adenovirus + Retrovirus 3 0.1
Measles virus 10 0.4
Modified Vaccinia Ankara virus (MVA) 8 0.3
mRNA Electroporation 5 0.2
Naked/Plasmid DNA 419 17
Naked/Plasmid DNA + Adenovirus 3 0.1




Naked/Plasmid DNA + Vesicular stomatitis virus 3 0.1
Newcastle disease virus 1 0
Listeria monocytogenes 25 1
Poliovirus 3 0.1
Poxvirus 70 2.8
Poxvirus + Vaccinia virus 36 1.5
Retrovirus 459 18.6
RNA transfer 48 1.9
Naked/Plasmid DNA + Vaccinia virus 3 0.1
RNA transfer + Naked/Plasmid DNA 1 0
RNA virus 5 0.2
Saccharomyces cerevisiae 9 0.4
Salmonella typhimurium 4 0.2
Semliki forest virus 2 0.1
Sendai virus 4 0.2
Shigella dysenteriae 1 0
Simian virus 2 0.1
siRNA 5 0.2
Sleeping Beauty transposon 10 0.4
Streptococcus mutans 1 0
Unknown 76 3.1
Total 2463
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targeted delivery of AAV vectors has shown a lot of advantages
over time, such as lower risk of vector distribution when compared
with liver delivery. There is the finding that, pre-existing humoral
immunity against AAV is a commonly encountered challenge in
liver delivery as well as blood delivery, however, this challenge
is absent in the case of muscle tissues, without the blockage of
transduction during gene therapy. This method was employed in
the early treatment of haemophilia B (with the restriction of
haemophilia B patients with missense mutations) through gene
therapy, demonstrating the safety and applicability of muscle-
directed gene therapy. It is however, not without its own limita-
tions though, pointing to the risk of triggering immune responses
by the pre-defined vector dose directed at the transgene product
[19,35]. The liver is a better option when this point is considered[36]. For cardiovascular diseases, heart muscle are a great target
for gene therapy with pre-clinical research on designing optimized
AAV vectors for that purpose still ongoing [37]. Calcium up-regu-
lation by percutaneous administration of gene therapy in cardiac
disease (CUPID) which was launched in 2008 has proven AAV1
vectors (same serotype as for LPLD) to be successful in safely
transducing human cardiac tissue following antegrade epicardial
coronary artery infusion in treating advanced heart failure
[27,38]. The strategy in this case take advantage of the over-
expression potential of the sarcoplasmic reticulum calcium ATPase
pump which is coded by SERCA2a and making it the target. During
heart failure, the protein expression of SERCA2a which is essential
for calcium (Ca2+) homeostasis is reduced and as a result produces
elevated end-diastolic and systolic Ca2+ levels which eventually
contributes to prolonging Ca2+ re-uptake [27]. The success of this
approach has been proven with a Phase I and Phase II trials
[25,36,38]. Though a relatively high vector doses are needed to
achieve therapeutic effect, the use of AAV-mediated in vivo gene
therapy discloses outstanding safety and efficiency [39,40]. With
strategies geared towards improving cell specificity as well as
transgene expression restriction, a danger shared by all the sero-
types in the intrinsic potential for off-target transduction resulting
from the broad tropism nature is obvious [39,41]. These challenges
notwithstanding, in addition to the AAV transcriptional and post-
transcriptional strategies that are in the pipeline to provide solu-
tions, engineered capsids modified to surmount these spotted
complications holds the promise for the use of AAV vectors to treat
patients with even a pre-existing anti-AAV humoral immunity
[20,41].
2.2. Self-inactivating (SIN) Channels
Self-inactivating (SIN) configuration refers to the deletions in
the U3 region of the 30 long-terminal repeats (LTR) located in
retroviral vector which results in a transcriptionally inactive 50
LTR via reverse transcription. This therefore reduces the transac-
tivation potential of the vector under consideration. This concept
has greatly enhanced the safety profile of applicable vectors, con-
firmed by a very recent approval in Germany for treating CGD.
The obvious advantage of this method over the gammaretroviral
vectors has made it the preferred method for gene transfer into
HSCs [42]. Currently, combining the Self-inactivating (SIN) con-
figuration with physiological promoters is in the clinical trial
scene as seen in the clinical trial status of SIN gammaretroviral
vector harbouring the elongation factor short (EFS) promoter
driving the expression of ILR2G, aimed at treating SCID-X1. Pro-
gress is already being recorded as obvious in the reconstitution
of T lymphocyte with partial restoration of humoral immunity
[43]. The advancement recorded in this method is that the vector
consists of a short myeloid-specific promoter which is derived
from the human c-FES gene that modulates the expression of a
codon-enhanced gp91phox cDNA [44]. Importantly, while retro-
viruses such as gammaretroviruses largely rely on the dissolution
of the nuclear membrane in the process of mitosis to deliver
their cargo into the target cell nucleus, the preintegration com-
plex of lentivirus vectors (pseudotypable with envelopes consist-
ing of vesicular stomatitis virus glycoproteins (VSVg)) is
translocated actively into the nucleus of the target cell, and as
a result its able to facilitate the efficient transduction of even
non-dividing cells such as HSCs via SIN-lentiviral vectors. The
easy pseudotyping effectively provides for a broad tropism
thereby enabling the effective transduction of target cells
(including CD34þ HSC). The contributions of molecular biology
and biotechnology in these areas did not completely push phar-
macotherapy aside, but facilitates the robust manufacturing as
well as purification protocols, that contribute to a superior
A.S. Odiba et al. / The Egyptian Journal of Medical Human Genetics 19 (2018) 69–75 73pharmaceutical quality of the vectors under consideration [45].
To emphasize what has been stated earlier, Phase I/II clinical tri-
als mostly in UK, Italy, the US (NCT01380990), Switzerland, Ger-
many and France with a focus on SIN-lentiviral vectors are on
the pipeline for more than a few PIDs (including WAS, CGD,
ADA-SCID) and for some non-PID using gene modified HSCs
(e.g. X-linked adrenoleukodystrophy (X-ALD), b-thalassaemia
and metachromatic leukodystrophy (MLD) [46]. About four
patients are recorded to have been treated with a lentiviral vec-
tor containing the EF1a promoter modulating the expression of
the ADA cDNA [47]. For X-CGD, a Phase I/II clinical study using
a SIN-lentiviral vector was recently approved in the UK and is
currently under regulatory review in Germany and Switzerland.
In contrast to the gammaretroviral vector employed in the first
WAS gene therapy trial, a typical strategy in this case of WAS
is the use of 1.6 kb stretch of the WAS gene’s at the upstream
of the regulatory region of the SIN-lentiviral vector to propel
the transgene expression of WAS in haematopoietic cells [48].
Restoration of the WAS protein expression was the obvious out-
come of this strategy in multiple lineages of leukocytes, leading
to an increased platelet counts. This ultimately enhances the
immune system functions as well as ameliorating the clinical
manifestation of the disease [46]. Hsa-miR-223 and MRP8 c-FES
genes code for promoters and their expression is a potential tar-
get for treating the functional defect in CGD which has a direct
effect on myeloid cells at the differentiation phase. This strategy
though has limitations in vivo could be fortified by fusing the
promoter elements with other regulatory sequences (e.g. the
strong viral CMV promoter, ubiquitously acting chromatin open-
ing element (UCOE) or Cathepsin G) [49]. Similarly, CathepsinG/
c-FES promoter is chosen to drive gp91phox in X-CGD in termi-
nally differentiating myeloid cells. Pre-clinical trials showed this
to be within the confines of expectation [49]. The outcome of
this could further enhanced microRNA (miR) target sequences
inserted into the lentiviral vector [50,51]. Modifying autologous
HSC not only helps in managing PIDs alone but offers treatment
potential for other monogenic disease such as lysosomal storage
disorders or mucopolysaccharide disorders and the leukodystro-
phies, which could also be cured by HLA-matched allogeneic
HSC transplantation. This offers very unique opportunity for
treating diverse metabolic disorders including a diseases that
entails a defect in an ATP-binding cassette transporter; ALD pro-
tein encoded by defected ABCD1 gene resulting in progressive
and irreversible X-ALD (severe cerebral demyelinating disorder)
[52,53]. The lentiviral vector was indispensable in these trials.
A demyelinating lysosomal storage disorder MLD (metachromatic
leukodystrophy) originating from arylsulphatase A (ARSA) defi-
ciency demonstrated in haematopoietic lineages is a viable
example [54]. Success in the transplantation of ex vivo gene
modified HSCs in adult patient buttresses the fact that the appli-
cation of the SIN-lentiviral vector is paramount, and also evident
in the use of mini-globin gene-contained SIN-lentiviral along
with its introns as well as its 30 -enhancer region, promoter
and a locus managed region. This also included two copies of
the 250-bp core element that constitutes the cHS4 chromatin
insulator. After about a year, the recipients became independent
of blood transfusions; one of the very obvious therapeutic advan-
tages related to the growth of a myeloid-restricted cell clone.
The lentiviral vector integration resulted in the induction of a
steady, unexpectedly spliced HMGA2 (a tumour suppressor gene)
that lead to a clonal growth that is benign [55,56]. Even though
there has been a recorded delay of the translation into clinical
practice due to the challenges of tissue constrained expression
of b-globin gene, this area of gene therapy has also over time
been interested in treating one of the most widespread class of
inherited disorders; the b-haemoglobinopathies. Against this lim-itation though, the application of gene therapy to the treatment
of b-globin deficiency-caused b-thalassaemia has begun. Lentivi-
ral vectors, apart from their application in ex vivo gene therapy,
have also been used in vivo in the treatment of Parkinson’s dis-
ease (a CNS pathology) and ocular diseases including Usher syn-
drome, Stargardt’s disease, and the wet variety of macular
degeneration type 1B, (http://www.oxfordbiomedica.co.uk/clini-
cal-trials-1/). High repertoire of clones causative of gene marked
haematopoiesis in bone marrow CD34þ cells as well as periph-
eral blood myeloid, B and T cells is usually linked with clinical
lentiviral vectors usage (e.g. X-ALD, WAS and MLD trials) in gene
therapy [57,58]. The results summarized from these studies were
preceded by reasonable follow-up for months, up to 62 months
in some cases [59]. Though this time frame of follow-up looks
short, evidence for the lack of clonal outgrowth and the lack of
transplantation-related side effects or adverse reaction in the
therapy or management of these monogenic diseases shows the
suitability of gene therapy, found useful in cases where suitable
HSC donors are not available. The use of lentiviral vectors in vivo
are not without limitations. Challenges of off-target location, as
well as the need for highly concentrated and purified particles,
achievable through the application of cell lines that are stable
exists [60]. The remarkable and pointed new and recent develop-
ment to one of the challenges is the development of engineered
lentiviral vectors with envelope pseudotypes [61]. Depending on
the expected outcome of the experiments or trials involving gene
transfer in post-mitotic tissues such as the insertion of the
human RPE65 gene into the retina for the correction of Leber
congenital amaurosis, non-integrating vectors can be made by
generating integration-deficient lentiviral vectors (IDLV), which
on transcription produces extrachromosomal DNA circles
[62,63]. This could be very functional in cases where only tran-
sient transgene expression (such as the vaccination approaches
in delivering transposases or designer nucleases) is needed.
[63–65].3. Conclusion
From the use of stem cell therapy to the science of targeted
specific gene correction, the advantages of gene therapy over
pharmacotherapy in the art of healing cannot be overstated.
The various opportunities like the same individual donor and
recipient identity in HSC transplant in order to combat the risk
of incompatibility, managing haemoglobin disorders such as
Sickle Cell disease and b-Thalassaemia, ocular gene transfer, can-
cer immunotherapy using gene-modified T cells, and targeted
specific gene correction places gene therapy ahead of many
other forms of treatment. There is room for so much improve-
ment on gene therapy because the opportunity to improve on
the AAV-derived Vectors and Self-inactivating (SIN) Channels.
This is in addition to the trending approach and strategy for
combating particular diseases via personalising treatments, and
there may actually be no better approach than tailoring a cure
to a specific disease in a particular individual. Instead of manag-
ing diseases and administering drugs which may have diverse
side-effects on the body, with gene therapy, the cause of the dis-
ease is targeted at the source and dealt with. The argument that
the application of gene therapy in treatment has not been with
us long enough to see the side effects it may present in subse-
quent generations does not stand much ground because it can-
not be denied that in gene therapy lies current and future
answers to treatment of insurmountable diseases that have
defied cure. With gene therapy, the mishaps of nature can be
corrected and we may well be on our way to reproducing ‘super
humans’.
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Large-scale manufacture and characterization of a lentiviral vector
produced for clinical ex vivo gene therapy application. Hum Gene Ther
2011;22:343–56.
[46] Hacein-Bey-Abina S, Blondeau J, Caccavelli L, Charrier S, Picard C, Dal-Cortivo
L, et al. Lentiviral vectorbased gene therapy for Wiskott-Alrdrich syndrome:
preliminary results from the French center. Mol Ther 2013;21:s117.
[47] Zhang L, Thrasher AJ, Gaspar HB. Current progress on gene therapy for primary
immunodeficiencies. Gene Ther 2013. http://dx.doi.org/10.1038/gt.2013.21.
[48] Scaramuzza S, Biasco L, Ripamonti A, Castiello MC, Loperfido M, Draghici E,
et al. Preclinical safety and efficacy of human CD34(þ) cells transduced with
lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol Ther
2013;21:175–84.
[49] Santilli G, Almarza E, Brendel C, Choi U, Beilin C, Blundell MP, et al. Biochemical
correction of X-CGD by a novel chimeric promoter regulating high levels of
transgene expression in myeloid cells. Mol Ther 2011;19:122–32.
[50] Lechman ER, Gentner B, van Galen P, Giustacchini A, Saini M, Boccalatte FE,
et al. Attenuation of miR- 126 activity expands HSC in vivo without
exhaustion. Cell Stem Cell 2012;11:799–811.
[51] Capotondo A, Milazzo R, Politi LS, Quattrini A, Palini A, Plati T, et al. Brain
conditioning is instrumental for successful microglia reconstitution following
hematopoietic stem cell transplantation. Proc Natl Acad Sci USA
2012;109:15018–23.
[52] Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera
I, et al. Hematopoietic stem cell gene therapy with a lentiviral
vector in X-linked adrenoleukodystrophy. Science (New York, NY)
2009;326:818–23.
[53] Byrne BJ, Falk DJ, Clément N, Mah CS. Gene therapy approaches for
lysosomal storage disease: next-generation treatment. Hum Gene Ther
2012;23:808–15.
[54] Montini E, Biffi A, Calabria A, Biasco L, Cesani M, Benedicenti F, et al.
Integration site analysis in a clinical trial of lentiviral vector based
hematopoietic stem cell gene therapy for metachromatic leukodystrophy. An
18 month follow- up. Mol Ther 2013;21:s119.
[55] Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, et al.
Transfusion independence and HMGA2 activation after gene therapy of human
b- thalassaemia. Nature 2010;467:318–22.
[56] Boulard F, Wang X, Taylor C, Qu J, Ferro L, Karponi G, et al. Safe G-CSF
mobilization of thalassemia patient CD34þ cells and effective globin gene
transduction for therapeutic infusion. Mol Ther 2013;21:s25.
[57] Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, et al.
Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-
Aldrich syndrome. Science 2013;341:1233151.
[58] Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral
hematopoietic stem cell gene therapy benefits metachromatic
leukodystrophy. Science 2013;341:1233158.
A.S. Odiba et al. / The Egyptian Journal of Medical Human Genetics 19 (2018) 69–75 75[59] Bartholomae CC, Cartier N, Hacein-Bey-Abina S, Kutschera I, Fischer A,
Cavazzana-Calvo M, et al. Integration profile of lentiviral vectors in gene
therapy for X-adrenoleukodystrophy. Mol Ther 2013;21:s106.
[60] Stewart HJ, Fong-Wong L, Strickland I, Chipchase D, Kelleher M, Stevenson L,
et al. A stable producer cell line for the manufacture of a lentiviral vector for
gene therapy of Parkinson’s disease. Hum Gene Ther 2010;22:357–69.
[61] Zhou Q, Buchholz CJ. Cell type specific gene delivery by lentiviral vectors: new
options in immunotherapy. Oncoimmunology 2013;2. 0-1.
[62] Yán~ez-Mun~oz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ.
Effective gene therapy with nonintegrating lentiviral vectors. Nat Med
2006;12:348–53.[63] Mátrai J, Chuah MK, Vanden Driessche T. Recent advances in lentiviral vector
development and applications. Mol Ther 2010;18:477–90.
[64] Hu B, Dai B, Wang P. Vaccines delivered by integration-deficient lentiviral
vectors targeting dendritic cells induces strong antigen-specific immunity.
Vaccine 2010;28:6675–83.
[65] Ebina H, Kanemura Y, Suzuki Y, Urata K, Misawa N, Koyanagi Y. Integrase-
independent HIV-1 infection is augmented under conditions of DNA damage
and produces a viral reservoir. Virology 2012;427:44–50.
